Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine

about

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

P2860

Q55361920-A2BA1B80-679F-41DB-B7DD-6A07C79678A5

P2860

Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine

Item

http://www.wikidata.org/entity/Q41487497

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Locally Advanced or Metastatic ...... ged Survival Under Gemcitabine

@en

type

Item

label

Locally Advanced or Metastatic ...... ged Survival Under Gemcitabine

@en

prefLabel

Locally Advanced or Metastatic ...... ged Survival Under Gemcitabine

@en

P1476

Locally Advanced or Metastatic ...... ged Survival Under Gemcitabine

@en

P2093

Anne Ploquin

http://www.w3.org/2001/XMLSchema#string

Capucine Baldini

http://www.w3.org/2001/XMLSchema#string

Guillaume Piessen

http://www.w3.org/2001/XMLSchema#string

Mohamed Hebbar

http://www.w3.org/2001/XMLSchema#string

Perrine Vuagnat

http://www.w3.org/2001/XMLSchema#string

Stephane Cattan

http://www.w3.org/2001/XMLSchema#string

Stephanie Truant

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

Management and prognosis of pancreatic cancer over a 30-year period.

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

P304

731-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21873/INVIVO.11122

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28652448

http://www.w3.org/2001/XMLSchema#string

P932

5566931

http://www.w3.org/2001/XMLSchema#string

Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine

about

P2860

P2860

Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932